Elan Corp. says the Federal Trade Commission has dropped its investigation into whether a tactic used by the drug maker impeded generics competition for Skelaxin, its muscle relaxant.
Related Results
Elan Announces Receipt Of FTC Letter Regarding SkelaxinElan Announces Approval of New Versions of Skelaxin and tizanidineKing Pharmaceuticals Reports FDA Approval of New Skelaxin LabelElan takes legal action over Skelaxin dealElan sells Sonata, Skelaxin for $850 million. (News).(to King Pharmaceuticals…
COPYRIGHT 2003 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning